A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
NCT06609226 · FLORAL Phase 3Recruiting
- Lead sponsor
- Novo Nordisk A/S (Industry)
- Enrollment
- 480 (estimated)
- Start date
- 10 Jan 2025
- Primary completion
- 30 Dec 2030 (estimated)
- Study completion
- 30 Dec 2030
- Last update posted
- 18 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Non randomized
- Intervention model
- Parallel
- Masking
- None
- Arms
- 5
Interventions
- Etavopivat A Drug
- Etavopivat B Drug
- Etavopivat C Drug
Conditions and primary outcome
- Sickle Cell Disease
- Thalassemia
Primary outcome
Number of treatment emergent adverse events (TEAEs), reported for each indication and age group separately (Baseline (week 0 of FLORAL) up to end of study (up to week 316)); Number of adverse reactions, reported for each indication and age group separately (Baseline (week 0 of FLORAL) up to end of study (up to week 316))
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06609226.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06609226 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.